Risperdal Jury “Blown Away” By Testimony On Study Manipulation; J&J Settles Texas Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
In the midst of a trial, Johnson & Johnson agrees to pay $158 million to settle a suit by the state of Texas alleging the company promoted Risperdal off-label to children. Two states previously won jury verdicts over the company’s marketing of the antipsychotic.
You may also be interested in...
J&J Challenges Risperdal Penalty As First Amendment Violation
In case that could impact use of state unfair trade practices statutes, Janssen seeks Supreme Court review of South Carolina’s $124 million judgment for Risperdal labeling and Dear Doctor letter.
FDA Warning Letter Is Inadmissible Hearsay, Arkansas Supreme Court Says In Tossing J&J Judgment
Court throws out $1.2 billion award to the state of Arkansas over Risperdal promotions.
Pharma v. State AGs: GlaxoSmithKline Is Fifth Firm To Challenge Hiring Of Private Counsel
GSK filed suit against the attorney general of Louisiana seeking a court order prohibiting the state from using private counsel in litigation over Avandia marketing; the state is seeking more than $10 billion in penalties.